Valneva reports further positive phase 3 immunogenicity and the first heterologous booster results for its inactivated, adjuvanted covid-19 vaccine vla2001

Saint- herblain (france), august 29 , 2022 – valneva se (nasdaq: valn; euronext paris: vla), a specialty vaccine company, today reported further positive phase 3 results for its inactivated, adjuvanted covid-19 vaccine vla2001. additional readouts from the company's pivotal vla2001-301 “cov-compare” trial showed persistent immunogenicity and first positive heterologous booster results following primary vaccination with chadox1-s (astrazeneca).
VALN Ratings Summary
VALN Quant Ranking